Mode
Text Size
Log in / Sign up

New therapies show promise for liver disease without cirrhosis

Share
New therapies show promise for liver disease without cirrhosis
Photo by Logan Voss / Unsplash

A large review of many clinical trials looked at treatments for adults with a liver condition called metabolic-dysfunction-associated steatohepatitis, or MASH, who do not yet have cirrhosis. This condition involves fat buildup and inflammation in the liver, often linked to metabolism problems. The review compared several new therapies that aim to improve how the body handles sugar and fat, reduce inflammation, or slow down liver scarring. These treatments were tested against a placebo, which is a shot or pill with no active medicine.

The main goal was to see if the treatments could help the liver heal. Researchers checked if the liver inflammation and fat went away without the scar tissue getting worse, or if the scar tissue improved without the liver condition getting worse. They also looked for a big drop in liver fat measured by a special scan. The review included over 12,000 people from many different trials.

The results showed that therapies focusing on improving metabolism and insulin sensitivity were the most helpful. For example, they made it about two to seven times more likely for a person to have their liver inflammation go away without more scarring, compared to placebo. They also helped a similar amount for improving liver scarring without making the inflammation worse. These treatments also consistently lowered liver fat on the scans.

However, it is important to know that many people on these new treatments still did not meet the strict goals set for the study. Between 35% and 70% of treated participants did not reach the desired liver improvements, while the placebo group had response rates between 11% and 18%. The review did not report detailed safety information, so we don't know about side effects from this summary.

This research suggests that focusing on metabolism could be a good base for future combination treatments for MASH. It highlights the need for therapies that provide lasting benefits. Because this is a review of many trials, it shows links between treatments and benefits but does not prove cause and effect. The certainty of the findings is limited because the original studies did not report all the statistical details.

What this means for you:
Metabolism-focused therapies show strong promise for improving early liver disease, but more work is needed for lasting results.
Share
More on Metabolic Dysfunction-Associated Steatohepatitis